Serological Assays for the Detection and Characterization of Influenza Viruses
Closed Solicitation Posted
This opportunity was awarded. See the award notice from .
- Solicitation number
- 75D30125R73235
- Agency
-
CDC Office of Acquisition Services
Centers for Disease Control and Prevention, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325413 In-Vitro Diagnostic Substance Manufacturing
- PSC
- Q301 Reference Laboratory Testing
- Place of performance
- Atlanta, Georgia, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Centers for Disease Control and Prevention (CDC) is seeking a contractor to provide serological assay testing services for influenza virus detection and characterization, specifically to support the CDC's Influenza Division through hemagglutination inhibition (HAI) assay testing of human sera and development of a new serology platform comparable to HAI. This is a competitive two-phase mandatory down-select procurement under NAICS code 325413 (In-Vitro Diagnostic Substance Manufacturing). Key contract requirements include performing HAI serological assays on human samples, developing an improved serology assay platform, and maintaining BSL-2 laboratory capability. The evaluation will use a best-value trade-off approach, with technical factors being significantly more important than past performance, and both being more important than cost. Critical dates include the Phase I letter of interest deadline of February 21, 2025, Phase I proficiency panel results due April 15, 2025, and Phase II proposals due May 22, 2025; however, Amendment 5 issued on December 11, 2025 has reopened the solicitation and resumed all procurement activities following a previous suspension.
This solicitation has no set-aside designation and anticipates awarding a single contract to one contractor. The contract will have a 12-month base period running from August 8, 2025 to August 7, 2026, with four optional 12-month extension periods extending through August 7, 2030, for a potential total contract duration of five years. The base requirement includes firm-fixed-price pricing for 6,000 test samples annually, with optional surge support lines for 9,000 and 10,500 tests per year, plus cost-plus-fixed-fee optional tasks for gap analysis and assay development activities. The contract will be performed primarily at the contractor's facility with some work performed at the CDC's Atlanta, Georgia campus. The small business size standard for this procurement is 1,250 employees.
Notice text
6 versions
Update #6 · Latest ·
Amendment 5 is being issued to re-open the solicitation and proceed with source selection activities. Reinstate Jennifer Gartzke as the point of contact. The attached SF30 contains additional information.
Update #5 ·
Amendment 4 is being issued to suspend the solicitation until further notice. Remove Jennifer Gartzke as the point of contact and add Vic Veguilla as the new point of contact. The attached SF30 contains additional information.
Update #4 ·
Amendment 3 is being issued to amend the timeline for Phase I. The new ship date for the assays is March 31, 2025 with a delivery date of April 1, 2025. The due date for results is April 15, 2025. Additional information will be provided in the packages to answer any lingering questions.
The objective of this contract is to support the Influenza Division through the testing of human sera via hemagglutination inhibition assay as well as develop a new serology platform that is comparable to hemagglutination inhibition assay.
The steps in Phase I are as follows:
-
- Letter of Interest – offerors shall email POC information to Contracting Officer
- Proficiency panel will be sent by CDC to intersted offerors
- Vendor shall email results to CDC Contracting Officer
- CDC Contractng Officer will notify each offeror of their pass/fail status for Phase I and if they are then able to proceed to Phase II
Update #3 ·
Amendment 2 is being issued to amend the timeline for Phase I and Phase II, update terms per new Executive Orders, add Q&A, and require a verification from intersted labs of BSL-2 laboratory capability. The finalized version of the solicitation amendment is attached, along with the Q&A document, and the solicitation with the track changes.
The objective of this contract is to support the Influenza Division through the testing of human sera via hemagglutination inhibition assay as well as develop a new serology platform that is comparable to hemagglutination inhibition assay.
This is Phase I of a a two phased multi-step mandatory down select solicitation. Interest for Phase I is due to the contracting officer no later than 2:00 PM EST February 21, 2025.
The steps in Phase I are as follows:
-
- Letter of Interest – offerors shall email POC information to Contracting Officer
- Proficiency panel will be sent by CDC to intersted offerors
- Vendor shall email results to CDC Contracting Officer
- CDC Contractng Officer will notify each offeror of their pass/fail status for Phase I and if they are then able to proceed to Phase II
Update #2 ·
Amendment 1 is being issued to push back the due dates for Phase I and Phase II. A PDF copy of the amendment is attached as well as a Word version showing the track changes to the document.
The objective of this contract is to support the Influenza Division through the testing of human sera via hemagglutination inhibition assay as well as develop a new serology platform that is comparable to hemagglutination inhibition assay.
This is Phase I of a a two phased multi-step mandatory down select solicitation. Interest for Phase I is due to the contracting officer no later than 2:00 PM EST February 21, 2025.
The steps in Phase I are as follows:
-
- Letter of Interest – offerors shall email POC information to Contracting Officer
- Proficiency panel will be sent by CDC to intersted offerors
- Vendor shall email results to CDC Contracting Officer
- CDC Contractng Officer will notify each offeror of their pass/fail status for Phase I and if they are then able to proceed to Phase II
Update #1 ·
The objective of this contract is to support the Influenza Division through the testing of human sera via hemagglutination inhibition assay as well as develop a new serology platform that is comparable to hemagglutination inhibition assay.
This is Phase I of a a two phased multi-step mandatory down select solicitation. Interest for Phase I is due to the contracting officer no later than 2:00 PM EST February 7, 2025.
The steps in Phase I are as follows:
-
- Letter of Interest – offerors shall email POC information to Contracting Officer
- Proficiency panel will be sent by CDC to intersted offerors
- Vendor shall email results to CDC Contracting Officer
- CDC Contractng Officer will notify each offeror of their pass/fail status for Phase I and if they are then able to proceed to Phase II
Files
Notice history
| Notice | Type | Posted |
|---|---|---|
| Serological Assays for the Detection and Characterization of Influenza Viruses | Award Notice | |
| This notice | Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| NAHLN Diagnostic Testing Services | Marketing and Regulatory Programs Business Services | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity